These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35348472)

  • 1. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
    Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
    Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting NAD
    Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
    Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
    [No Abstract]   [Full Text] [Related]  

  • 3. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
    Matro J; Giubellino A; Pacak K
    Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
    Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
    Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
    [No Abstract]   [Full Text] [Related]  

  • 9. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
    Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment.
    Facchin C; Perez-Liva M; Garofalakis A; Viel T; Certain A; Balvay D; Yoganathan T; Woszczyk J; De Sousa K; Sourdon J; Provost J; Tanter M; Lussey-Lepoutre C; Favier J; Tavitian B
    Theranostics; 2020; 10(8):3518-3532. PubMed ID: 32206105
    [No Abstract]   [Full Text] [Related]  

  • 14. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
    Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
    Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
    Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
    Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
    Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
    Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
    Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
    BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.